Musk: The company’s second product is called Blindsight, intended to give vision to people who are completely blind or have never seen light
Neuralink founder Elon Musk posted on X on October 30, 2026, that the company’s second product is called Blindsight, intended to give vision to people who are completely blind or have never seen light. He said the product was ready from an engineering standpoint and was now waiting for regulatory approval. The post cited his previous statement about the first product, Telepathy, which said it could enable high-speed communication through thought with computers or other people, and that its output bandwidth would in the future far exceed the fastest human speech or typing speed.
Neuralink’s website says Blindsight captures images through a camera and wirelessly transmits them to an implant, directly stimulating the visual cortex to generate visual perception, bypassing the eyes and optic nerve pathway. On September 17, 2024, the company announced that it had received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation, which applies to individuals with visual impairments and is intended to accelerate development and review. FDA breakthrough designation does not constitute market approval, and the device still must meet safety and effectiveness standards. As of October 2026, Neuralink’s website listed the visual prosthesis trial as an upcoming project and opened patient registration; the device control and speech restoration trial was listed as active. There are no publicly disclosed human Blindsight implant results.
Musk has previously said that the initial resolution would be relatively low, similar to early video game graphics, and that the long-term goal includes surpassing natural vision and extending to infrared, ultraviolet and other bands. The company has previously tested related technology in monkeys. As of January 2026, Neuralink’s N1 implant, used for motor control and other purposes, had been used in about 21 participants worldwide. Blindsight’s regulatory path still depends on FDA review of human trial or marketing applications, and the statement that it is ready from an engineering standpoint does not change the current status that the device has not yet been shown in humans to restore usable vision.
Original sources:
Title: Our second product is called Blindsight... Publisher: Elon Musk (@elonmusk) Publication date: 2026-10-30 URL: https://x.com/elonmusk/status/2116019939056513218 Source type: social media post Verification: this reading covered the full post and quoted material, verification date 2026-10-30 Supported content: Blindsight is the second product, gives sight to people who are completely blind or have never seen light, ready from an engineering standpoint and waiting only for regulatory approval
Title: Neuralink Receives Breakthrough Device Designation for Blindsight Publisher: Neuralink Publication date: 2024-09-17 URL: https://neuralink.com/updates/neuralink-receives-breakthrough-device-designation-for-blindsight/ Source type: company website update Verification: this reading covered the full page, verification date 2026-10-30 Supported content: received FDA Breakthrough Device Designation, for individuals with visual impairments
Title: Visual Prosthesis | Neuralink Publisher: Neuralink Publication date: page continuously updated URL: https://neuralink.com/trials/visual-prosthesis/ Source type: company website Verification: this reading covered the full page, verification date 2026-10-30 Supported content: camera-to-visual-cortex pathway, explanation of breakthrough designation, patient registration, trial status as upcoming
ABAB AI Insight
This statement comes against the backdrop of Neuralink having already conducted motor control and speech restoration clinical trials with Telepathy (the N1 implant) in multiple countries. The company received FDA Breakthrough Device Designation for Blindsight in September 2024; this program prioritizes review for devices related to serious or irreversible conditions, but it does not authorize marketing or confirm safety and effectiveness. The website currently labels the visual prosthesis trial as “upcoming,” while the device control and speech trials are active, showing differences in regulatory progress between the two product lines.
On capital and pathway, Neuralink has completed multiple funding rounds, including Series E in 2025, and has conducted trials in the United States, Canada, the United Kingdom and elsewhere. The statement that the product is ready from an engineering standpoint puts regulatory approval on the critical path: breakthrough designation speeds communication and priority review, but human trials still require an investigational device exemption or equivalent approval. The company had previously tested similar visual stimulation in animal models, but public information has not confirmed a human Blindsight implant.
Compared with historical cases, this is similar to early retinal prostheses such as Argus II and visual cortex stimulation experiments. The similarity is that electrical stimulation is used to bypass damaged peripheral visual pathways and generate light perception or low-resolution perception; the difference is that Neuralink is using a high-channel-count implant and camera input, with the goal expanding from simple light perception to recognizable patterns, and Musk publicly compared the initial effect to early video game graphics while mentioning future vision beyond natural sight. The key risks are the spatial resolution of visual cortex stimulation, long-term stability, and the brain plasticity of people who have never seen light, all of which require human data to validate.
Specifically, the statement that the product is ready from an engineering standpoint moves the product from an R&D narrative to a regulatory approval node, but it does not change the current status that Blindsight has not yet been shown in humans to restore usable vision. What it changes is the company’s external communication pace—from trial progress updates to product naming and waiting for regulatory review. Necessary conditions include FDA decisions on human trial applications, public safety and preliminary efficacy data, and whether the resolution reaches functional vision rather than merely light perception. Indicators to watch are whether Neuralink’s website trial status changes from “upcoming” to “active,” ClinicalTrials.gov registration, and any disclosure of the first human results.
ABAB News · Cognitive Laws
- Breakthrough Device Designation speeds up the review process, but it does not mean safety and effectiveness have already been proven.
- A statement that a product is ready from an engineering standpoint moves the product from R&D to regulatory approval; human data remains the validation threshold.
- Visual cortex stimulation can bypass peripheral damage, but resolution and plasticity determine whether functional vision can be achieved.